Vancouver’s medical biotech companies — Absci, CytoDyn and a new player, Capsigen — are on the leading edge of a global revolution aimed at developing new technologies to produce medicines and tools for gene therapy.
Biotech, or life sciences companies, are a relatively new industry, but they already represent a $30 billion business in Washington.
In 2021 alone, the industry reported record investments, with companies raising almost $5 billion — including initial stock offerings for six life science companies, according to a news release from Life Science Washington.